These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 282940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
    Plunkett W, Iacoboni S, Keating MJ.
    Scand J Haematol Suppl; 1986; 44():51-9. PubMed ID: 3457439
    [No Abstract] [Full Text] [Related]

  • 4. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP, Finch LR, Snook M, Wiley JS.
    Cancer Res; 1987 Jun 15; 47(12):3130-5. PubMed ID: 3472653
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Paul CY, Gahrton CG, Peterson CO.
    Cancer Res; 1985 May 15; 45(5):2373-5. PubMed ID: 3986778
    [Abstract] [Full Text] [Related]

  • 6. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM, Rustum YM, Preisler HD.
    Semin Oncol; 1985 Jun 01; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract] [Full Text] [Related]

  • 8. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
    Preisler HD, Rustum Y, Priore RL.
    Eur J Cancer Clin Oncol; 1985 Jan 01; 21(1):23-30. PubMed ID: 4038655
    [Abstract] [Full Text] [Related]

  • 9. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
    Tanaka M, Yoshida S.
    Leuk Res; 1989 Jan 01; 13(10):931-6. PubMed ID: 2586146
    [Abstract] [Full Text] [Related]

  • 10. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 01; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologically directed design of leukemia therapy.
    Plunkett W, Heinemann V, Estey E, Keating M.
    Haematol Blood Transfus; 1990 May 01; 33():610-3. PubMed ID: 2182451
    [Abstract] [Full Text] [Related]

  • 12. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec 01; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 13. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 14. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Eur J Cancer Clin Oncol; 1983 Jul 01; 19(7):941-4. PubMed ID: 6576907
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
    Roberts D, Peck C, Hilliard S, Wingo W.
    Cancer Res; 1979 Oct 01; 39(10):4048-54. PubMed ID: 476642
    [Abstract] [Full Text] [Related]

  • 16. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M, Yoshida S.
    Jpn J Cancer Res; 1987 Aug 01; 78(8):851-7. PubMed ID: 3115933
    [Abstract] [Full Text] [Related]

  • 17. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
    Burke PJ, Karp JE, Braine HG, Vaughan WP.
    Cancer Res; 1977 Jul 01; 37(7 Pt 1):2138-46. PubMed ID: 266416
    [No Abstract] [Full Text] [Related]

  • 18. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.
    Chou TC, Arlin Z, Clarkson BD, Phillips FS.
    Cancer Res; 1977 Oct 01; 37(10):3561-70. PubMed ID: 332337
    [No Abstract] [Full Text] [Related]

  • 19. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
    Harris AL.
    Cancer Res; 1981 Jul 01; 41(7):2977-9. PubMed ID: 6941850
    [No Abstract] [Full Text] [Related]

  • 20. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T, Kobayashi K, Nakamura S, Ohtake S, Itoh K, Kanno M, Hirai J, Yasushi, Matsuda TT.
    Gan To Kagaku Ryoho; 1988 Apr 01; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.